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PDefining the Role of Basal
and Prandial Insulin for Optimal Glycemic Control
Edward S. Horton, MD
Boston, Massachusetts
Type 2 diabetes mellitus is a progressive disease characterized by early impairment of beta-cell function and
ultimately loss of beta-cell mass. Hence, a single daily injection of a long-acting insulin is commonly initiated
after intensification of oral antihyperglycemic therapy. Hemoglobin A1C should be measured every 3 months
and therapy adjusted if the target is not met. As beta-cell function continues to decline, it is often necessary to
add exogenous bolus insulin therapy, using short-acting insulin analogs or regular insulin. Alternatively, the use
of pre-mixed insulin preparations, combining both long-acting and short-acting insulins, may be used. (J Am
Coll Cardiol 2009;53:S21–7) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.008w
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Piabetes is highly prevalent in patients with cardiovascular
CV) disease, and its optimal management is critical to
educe adverse outcomes. The pathogenesis of type 2
iabetes mellitus (T2DM) is complex and involves progres-
ive impairment of pancreatic beta-cell function with loss of
ormal patterns of glucose-stimulated insulin secretion,
xcess glucagon secretion, and peripheral insulin resistance.
he result of these abnormalities is hyperglycemia, both in
he fasting and the post-prandial states (1–3). Successful
reatment of hyperglycemia in T2DM requires an under-
tanding of the factors that regulate fasting blood glucose
oncentrations and the excessive increase in glucose that
ccurs after meals.
There are now several classes of oral antihyperglycemic
rugs (OADs), as well as some injectable peptide hormones,
hat target different defects in glucose regulation and are
ffective either as monotherapy or in combination with
ther agents that have complementary mechanisms of ac-
ion (Table 1). There are also a large number of insulin
reparations available, including human insulin and insulin
nalogs, ranging from long-acting basal insulins that pro-
ide stable plasma insulin concentrations for up to 24 h or
onger, as well as short-acting insulins that are used for
olus therapy to control post-prandial hyperglycemia. Var-
ous pre-mixed insulin preparations that combine both
ong-acting and short-acting insulins are also available for
se (Table 2). Achieving optimal glycemic control in people
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ccepted November 6, 2008.ith T2DM is challenging for CV specialists and requires
he effective use of both OADs and insulin replacement
herapy to achieve target hemoglobin A1C (A1C) levels as
lose to normal as possible (6%) and at a minimum 7%
ithout excessive risk of hypoglycemia or other unaccept-
ble side effects. An updated consensus statement on the
anagement of hyperglycemia in T2DM, recently pub-
ished by the American Diabetes Association and the
uropean Association for the Study of Diabetes, provides
n algorithm that can serve as a general guideline (4).
auses of Hyperglycemia in T2DM
asting hyperglycemia. In the fasting state, plasma glu-
ose concentration is normally maintained at 70 to 100
g/dl by a balance between glucose uptake in both insulin-
ependent (e.g., skeletal muscle and adipose tissue) and
oninsulin-dependent (e.g., central nervous system and
lood elements) tissues and glucose production by the liver
hrough a combination of glycogenolysis and gluconeogen-
sis. Hepatic glucose production is regulated primarily by
nsulin, glucagon, and the availability of substrates for
luconeogenesis; although during situations of stress, the
ounter-regulatory hormones epinephrine, norepinephrine,
ortisol, and growth hormone also play a role to increase
epatic glucose production. In T2DM, fasting hyperglyce-
ia results primarily from excessive hepatic glucose produc-
ion in the context of insulin resistance in both the liver and
he peripheral tissues, decreased insulin secretion, and excess
lucagon secretion. Agents that reduce insulin resistance
particularly in the liver), increase plasma insulin concentra-
ions, or decrease glucagon secretion can effectively reduce
asting hyperglycemia.
ost-prandial hyperglycemia. After meal ingestion, insu-in is normally secreted in a biphasic manner and gluca-
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Insulin for Optimal Glycemic Control February 3, 2009:S21–7gon secretion is suppressed. The
early, rapid release of insulin
(first phase secretion) and sup-
pression of glucagon play a major
role in regulating hepatic glucose
metabolism; hepatic glucose pro-
duction rapidly decreases and net
hepatic glucose uptake occurs. In
addition, insulin stimulates pe-
ripheral glucose uptake in skele-
tal muscle and adipose tissue.
The post-prandial increase in in-
sulin secretion and decrease in
glucagon is potentiated by the
intestinal release of the incretin
ormones glucagon-like peptide-1 and glucose-dependent
nsulinotropic polypeptide, both of which increase glucose-
ependent insulin secretion from pancreatic beta cells (the
ncretin effect) and suppress glucagon secretion from the
lpha cells. Decreases in all of these responses occur in
2DM, resulting in excessive increases in plasma glucose
fter meals. Normally, post-prandial blood glucose concen-
ration reaches a peak (usually 140 mg/dl) at about 45 to
0 min after food ingestion and returns to baseline levels by
to 4 h, depending on the composition of the meal, as well
s the rates of gastric emptying, food digestion, and absorp-
ion. In T2DM, peak blood glucose levels typically occur 1
o 2 h after a meal, are much higher than normal, and are
low to return to baseline values. This results in sustained
yperglycemia, which is associated with increased oxidative
tress, impaired endothelial function, and other deleterious
ffects on the vascular system. Effective treatment for
ost-prandial hyperglycemia is therefore a major target for
reatment to reduce long-term risks and complications of
yperglycemia.
1C. A1C is a measure of the glycation of the hemoglobin
olecule over the lifespan of red cells and is expressed as a
ercentage of the total hemoglobin. In people with a normal
ed cell production rate and survival time, normal values are
etween 4% and 6%, using current methods and standards.
he A1C provides an indication of average blood glucose
oncentrations during the preceding 2 to 3 months and is
onsidered to be the reference standard for assessing overall
Abbreviations
and Acronyms
A1C  hemoglobin A1C
CI  confidence interval
CV  cardiovascular
HR  hazard ratio
MI  myocardial infarction
OAD  oral
antihyperglycemic drug
T2DM  type 2 diabetes
mellitus
TZD  thiazolidinedione
echanisms of Action of Oral Antihyperglycemic Agents and Inject
Table 1 Mechanisms of Action of Oral Antihyperglycemic Agen
Drug Class
1Insulin
Sensitivity
2Glucose
Production
Metformin X
Sulfonylureas
Glinides
TZDs X
-glucosidase inhibitors
DPP-IV inhibitors X
GLP-1 mimetics X
PramlintideHO  carbohydrate; DPP  dipeptidyl peptidase; GLP  glucagon-like peptide; T2DM  type 2 diabetelycemic control in people with diabetes. The A1C mea-
urement does not distinguish between the contributions of
asting versus post-prandial hyperglycemia, although some
eneral assumptions can be made. When fasting blood
lucose levels are maintained close to normal, for example,
ost-prandial increases in glucose that occur throughout
ost of the day will have a relatively greater impact on A1C
evels than when fasting glucose levels are also high.
herefore, treatment strategies to lower A1C to as close to
ormal as possible must address improving both fasting and
ost-prandial glucose control. Goals of therapy dictate that
1C should be as close to normal as possible without
ncurring an excessive risk of hypoglycemia, and in general
o 7%, in individual patients. Recent estimates from
ational Health and Nutrition Examination Survey data
ndicate that, in the U.S., progress is being made in
chieving these goals, but there is still a long way to go. The
ercentage of people with diagnosed diabetes with A1C
7% has increased from 37% in 1999 to 2000 to 56.8% in
003 to 2004 (5) (Fig. 1).
Peptide Hormones Used to Treat T2DM
d Injectable Peptide Hormones Used to Treat T2DM
ulin
tion
2Glucagon
Secretion
Retard CHO
Absorption
Effect of
Body Weight
2
1
1
11
X ¡
X ¡
X 22
X 22
nsulin and Insulin Analogreparations Available for Treatment of T2DM
Table 2 Insulin and Insulin AnalogPreparations Available for Treatment of T2DM
Type of Insulin
Onset of
Action Peak Action
Duration of
Action
Very-rapid-acting
Insulin lispro 5–15 min 30–90 min 3–5 h
Insulin aspart 5–15 min 30–90 min 3–5 h
Insulin glulisine 5–15 min 30–90 min 3–5 h
Rapid-acting
Soluble (regular)
human insulin
30–60 min 2–3 h 5–8 h
Intermediate–acting
Isophane (NPH) insulin 1.5–4 h 4–10 h 10–16 h
Long-acting
Insulin glargine 1–3 h No pronounced peak 24 h
Insulin detemir 1–3 h No pronounced peak 24 h
Pre-mixed insulins
70/30 human insulin 30–60 min Biphasic 10–16 h
50/50 human insulin 30–60 min Biphasic 10–16 h
75/25 lispro insulin 5–15 min Biphasic 10–16 h
50/50 lispro insulin 5–15 min Biphasic 10–16 h
70/30 aspart insulin 5–15 min Biphasic 10–16 h
PH  neutral protamine Hagedorn; T2DM  type 2 diabetes mellitus.able
ts an
1 Ins
Secre
X
X
X
Xs mellitus; TZD  thiazolidinedione.
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lood Glucose and CV Disease Risk
t is now well established that elevated A1C levels are
losely related to both microvascular and macrovascular
omplications of diabetes (6–9). However, the relative
ontributions of fasting and post-prandial glucose concen-
rations to CV disease risk are less defined (10). The bulk of
vidence supports the conclusion that post-prandial hyper-
lycemia is a more important determinant of CV disease
isk than fasting glucose (11–16), which has resulted in
ncreased emphasis on treating post-prandial hyperglycemia
n T2DM management.
Two recent trials assessed the effects of intensive versus
tandard glucose targets on CV events. The ACCORD
Action to Control Cardiovascular Risk in Diabetes) study
ncluded 10,251 subjects (mean age 62 years) with T2DM
nd either confirmed CV disease or combinations of risk
actors and/or conditions suggesting a high likelihood of
V disease (17). The A1C targets were 6% (intensive
roup) and 7% to 7.9% (standard group). To meet these
oals, study investigators could use all currently available
lucose-lowering drugs. The primary outcome was a com-
osite of CV death, nonfatal myocardial infarction (MI), or
troke. At 1 year, median A1C levels were 6.4% and 7.5% in
he intensive-therapy and standard-therapy groups, respec-
ively, and these levels were maintained throughout a mean
ollow-up of 3.5 years. The primary outcome occurred in
.9% and 7.2% of patients, respectively (hazard ratio [HR]:
.90, 95% confidence interval [CI]: 0.78 to 1.04, p  0.16).
ll-cause mortality was significantly higher in the intensive-
herapy group, 5.0% versus 4.0% (HR: 1.22, 95% CI: 1.01
o 1.46, p  0.04). In contrast, nonfatal MI was signifi-
antly lower in the intensive-therapy group, 3.6% versus
Figure 1 NHANES: A1C Levels in Diabetes, 1999 to 2004
Data from the National Health and Nutrition Examination Survey (NHANES) indi-
cate that the unadjusted geometric mean hemoglobin A1C (A1C) among U.S.
men and women 20 years of age with diagnosed diabetes has decreased
since 1999 (5)..6% (HR: 0.76, 95% CI: 0.62 to 0.92, p  0.004). There fas no significant difference in the rate of stroke. Because of
he increased all-cause mortality rates in the intensive-
herapy group versus the standard-therapy group, the inten-
ive regimen was discontinued and patients in this arm of
he study were switched to standard glycemic therapy.
The ADVANCE (Action in Diabetes and Vascular
isease: Preterax and Diamicron Modified-Release Con-
rolled Evaluation) trial included 11,140 subjects who had
2DM, were 55 years of age or older (mean age 66 years),
nd had either a history of CV disease or at least 1 other CV
isk factor (18). The A1C goal in the intensive group was
6.5%, whereas that in the standard group was based on
ocal guidelines. The glucose-lowering regimen used in the
ntensive arm was based on a modified-release formulation
f the sulfonylurea gliclazide; participants in the other arm
ontinued with their usual glucose-lowering regimens ex-
ept gliclazide. The macrovascular primary outcome was a
omposite of CV death, MI, and stroke. The microvascular
rimary outcome was a composite of new/worsening ne-
hropathy (development of macroalbuminuria, doubling of
erum creatinine to a level of at least 2.26 mg/dl, need for
enal replacement, or death caused by renal disease), reti-
opathy (development of proliferative retinopathy, macular
dema, or diabetes-related blindness; or retinal photocoag-
lation therapy). After a median of 5 years, mean A1C
alues were 6.5% and 7.3% in the intensive-treatment and
tandard-treatment groups, respectively. The macrovascular
rimary outcome occurred in 10.0% and 10.6% of patients,
espectively (HR: 0.94, 95% CI: 0.84 to 1.06, p  0.32).
he microvascular primary outcome occurred in 9.4% and
0.9% of patients, respectively (HR: 0.86, 95% CI: 0.77 to
.97, p  0.01). The combined primary outcomes occurred
n 18.1% and 20.0% of patients, respectively (HR: 0.90, 95%
I: 0.82 to 0.98, p  0.01). All-cause mortality and
econdary CV outcomes did not differ significantly between
he groups (Fig. 2).
The ACCORD and ADVANCE results indicate that in
atients with diabetes who are at high risk for CV events it
ould be prudent to set a goal A1C of approximately 7%.
he American Diabetes Association recommends a fasting
lucose of 70 to 130 mg/dl and a post-prandial target of
180 mg/dl (19). Ongoing clinical outcomes trials may
rovide further clarification.
In the VADT (Veterans Affairs Diabetes Trial) study, 1,791
eterans with T2DM were randomized to intensive versus
tandard treatment (20). Among trial participants, approxi-
ately 40% had a prior CV event, whereas approximately 80%
ere hypertensive; most subjects were also overweight or obese.
hese subjects had higher glucose levels than participants in
ither ACCORD or ADVANCE, with a baseline A1C of
.5%. A variety of drugs was used in both arms, with A1C
evels reduced to 6.9% in the intensive arm and 8.4% in the
tandard-treatment group. Blood glucose levels had no impact
n outcomes; both groups had fewer events than expected,
hich may have been a result of the general control of other riskactors. Interestingly, a substudy found that coronary artery calci-
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Insulin for Optimal Glycemic Control February 3, 2009:S21–7cation correlated with retinopathy. As with ADVANCE, there
as no suggestion that more intensive antidiabetes therapy in-
reased CV events.
anagement of Hyperglycemia in T2DM
undamental to all treatment regimens for managing hy-
erglycemia in T2DM is the education of patients to
elf-manage their disease. The establishment of a lifestyle
rogram that includes a healthy diet, physical activity, and
eight loss of 5% to 10% of initial body weight, for those
ho are overweight or obese, is also critical. These strategies
Figure 2 ACCORD and ADVANCE: Treatment Effects
(A) ACCORD (Action to Control Cardiovascular Risk in Diabetes): treatment
effects of intensive glycemic control on primary outcome. The primary outcome
in the ACCORD trial was a composite of cardiovascular death, myocardial
infarction, and stroke. Hazard ratio: 0.90 (95% confidence interval: 0.78 to
1.04), p  0.16. See text for specific treatment goals. Reprinted with permis-
sion from the ACCORD Study Group (17). Copyright © 2008 Massachusetts
Medical Society. All rights reserved. (B) ADVANCE (Action in Diabetes and Vas-
cular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation):
treatment effects of intensive glycemic control on primary macrovascular end
point. The primary macrovascular end point in the ADVANCE study was a com-
posite of cardiovascular death, myocardial infarction, and stroke. Hazard ratio:
0.94 (95% confidence interval: 0.84 to 1.06), p  0.32. See text for specific
treatment goals. Reprinted with permission from the ADVANCE Collaborative
Group (18). Copyright © 2008 Massachusetts Medical Society. All rights
reserved.lone, if successfully implemented, can result in significant improvement in both fasting and post-prandial blood glu-
ose levels and in A1C. However, many patients are not
uccessful in achieving these goals and will require therapy
ith OADs or insulin to manage their glucose levels. In
ddition, lifestyle modifications require time to achieve
esults; current recommendations dictate beginning OADs
mmediately, usually metformin alone or in combination
ith another oral agent such as a sulfonylurea, thiazo-
idinedione (TZD), or dipeptidyl-peptidase-IV inhibitor as
nitial combination therapy. In some patients with severe
yperglycemia, insulin may also be required as initial therapy.
The next major recommendation directed toward CV
pecialists is to avoid clinical inertia in advancing therapy to
chieve the A1C goal. A1C should be measured every 3
onths and therapy adjusted if targets are not met. Com-
on guidelines dictate the following: metformin doses
hould be gradually titrated upward to achieve maximal
ffectiveness (usually 2,000 to 2,500 mg/day) while minimiz-
ng gastrointestinal side effects and a second oral agent or
nsulin should be added if needed. The most commonly used
nd least expensive oral combination is metformin plus a
ulfonylurea; however, hypoglycemia caused by the long-acting
ffects of sulfonylureas on insulin secretion may be a limiting
actor. Shorter-acting insulin secretagogues such as nateglinide
r repaglinide carry less risk of hypoglycemia and may be
seful in this situation. Recently, sitagliptin, a dipeptidyl-
eptidase-IV inhibitor, has been shown to be as effective as the
ulfonylurea glipizide when added to metformin, and shows a
ignificantly lower risk of hypoglycemia (21).
Another commonly used combination is metformin plus
TZD, which decreases both fasting and post-prandial
lucose by reducing hepatic glucose production and improv-
ng peripheral insulin sensitivity. The major disadvantages
f TZDs are the associated weight gain and fluid retention
hat can result in heart failure in some patients (22). Recent
oncern about a possible increased risk of MI with rosigli-
azone (23), but not with pioglitazone (24), has prompted
aution in using rosiglitazone in patients at high risk for CV
isease (4). However, an interim analysis of another rosigli-
azone trial showed no statistically significant effects on MI,
lthough there seemed to be an increased risk of congestive
eart failure (25). In the ADOPT (A Diabetes Progression
rial) study, rosiglitazone was associated with higher rates
f upper and lower limb fractures compared with metformin
r glyburide (26). This effect was more pronounced in
omen than in men. In the PERISCOPE (Pioglitazone
ffect on Regression of Intravascular Sonographic Coronary
bstruction Prospective Evaluation) study, pioglitazone
as associated with a higher rate of fractures compared with
limepiride (27).
Alpha-glucosidase inhibitors, such as acarbose and migli-
ol, may also be used to improve post-prandial hyperglyce-
ia and reduce A1C levels in T2DM. By slowing the rate
f digestion and absorption of complex carbohydrates in the
ntestine, alpha-glucosidase inhibitors blunt post-prandial
ncreases in blood glucose. However, many patients find the
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February 3, 2009:S21–7 Insulin for Optimal Glycemic Controlastrointestinal side effects associated with this drug class to
e a significant deterrent, despite the option of gradual
itration to minimize gastrointestinal problems; these
gents, therefore, are not used extensively in the U.S. They
an be very effective, however, in people who traditionally
at a diet high in complex carbohydrates.
Other effective approaches to improve glycemic control,
ith the added benefit of achieving significant weight loss in
2DM, include treatment with exenatide or pramlintide,
oth given by injection 2 to 3 times daily. Exenatide is a
ong-acting glucagon-like peptide-1 mimetic that increases
lucose-dependent insulin secretion and restores suppres-
ion of glucagon secretion in response to meals. It also
elays gastric emptying, increases satiety, and results in
eight loss in the majority of patients. Both fasting and
ost-prandial glucose levels are improved with exenatide,
hich exerts its major effect post-prandially. Some cases of
ancreatitis associated with exenatide treatment, including
cute hemorrhagic pancreatitis, have been reported (28,29).
n the basis of review of these cases, the U.S. Food and
rug Administration has asked the manufacturer to
trengthen the labeling of acute pancreatitis in the product
abel. Pramlintide also decreases post-prandial hyperglyce-
ia, mainly by decreasing the rate of gastric emptying, and
s associated with weight loss in most patients.
Because T2DM is a progressive disease characterized by
arly impairment of beta-cell function and ultimately loss of
eta-cell mass, insulin replacement therapy is required for
any patients. Most OADs lose effectiveness over time,
equiring frequent monitoring of A1C levels and adjust-
ent of the treatment regimen to achieve or maintain
dequate glycemic control. In the ADOPT study, treatment
ith the sulfonylurea glyburide showed a less durable effect
han treatment with metformin, and both were less effective
n maintaining long-term glucose control than the TZD
osiglitazone, suggesting that beta-cell function was better
reserved with rosiglitazone (26). Maintenance of glycemic
ontrol with insulin, by targeting both fasting and post-
randial hyperglycemia, may also be effective in preserving
eta-cell function and mass by reducing glucose toxicity and
xidative stress, as both of these effects have been implicated
n the process of beta-cell destruction (2).
nsulin Therapy in T2DM
he most common first step in the initiation of insulin
herapy is to use a single daily injection of a long-acting
nsulin analog such as glargine or detemir insulin. These
odified insulins are absorbed slowly and result in nearly
onstant basal plasma concentrations, which in most pa-
ients last for 24 h or longer. Long-acting insulins differ
rom the intermediate-acting neutral protamine Hagedorn
nsulin, which has a shorter duration of action, requires at
east 2 injections daily, and tends to show less reproducible
harmacokinetics in some patients. Although the single rnsulin injection is most commonly given in the evening, it
ay be given at any time during the day; dose adjustments
re based on the fasting glucose concentration, usually
argeting a value of 100 to 120 mg/dl. Adjustments are
ade every 2 to 3 days, until the desired target fasting
lucose is achieved without significant hypoglycemia at
ther times.
As beta-cell function declines, it often becomes necessary to
dd exogenous bolus insulin therapy, using rapid-acting insulin
nalogs or regular human insulin, to control post-prandial
yperglycemia. Rapid-acting analogs such as lispro, aspart, or
lulisine insulin are generally preferable to regular human
nsulin because they are more rapidly absorbed and their action
ore closely mimics the normal physiological insulin response
o meals. The dosage is adjusted based on both the pre-meal
lood glucose concentration and the estimated carbohydrate
ontent of the meal, using a pre-determined correction factor
or treating elevated glucose levels and an insulin–carbohydrate
atio to match the insulin dose to the carbohydrate load. These
alues are determined on an individual basis for each patient
nd are designed to replicate as closely as possible the normal
atterns of insulin secretion throughout the day. Excellent
eviews are available that discuss the various insulin prepara-
ions and their uses (30).
An alternative approach to basal–bolus therapy is the use
f pre-mixed insulin preparations that combine both long-
cting and short-acting insulins in various combinations,
ncluding 50:50, 75:25, and 70:30 mixtures of insulin
nalogs or human insulin. These preparations are usually
dministered 2 to 3 times daily before meals to provide a
ore convenient regimen for patients than the 4 daily
njections required by basal–bolus therapy. In many pa-
ients, this approach is adequate, although a recent study
ound that a regimen using 3 daily injections of pre-mixed
nsulins was less effective in lowering A1C than a basal–
olus regimen involving 4 injections daily (31).
An increasing number of people with T2DM are now
sing insulin pumps to administer continuous subcutaneous
nsulin infusions of rapid-acting insulin analogs to simulate
ormal insulin secretory patterns throughout the entire 24-h
eriod. With these pumps, multiple basal rates may be
rogrammed to adjust for changing insulin requirements at
ifferent times of the day, and different patterns of bolus
nfusions may be chosen to match individual needs. Insulin
umps, combined with continuous glucose monitoring sys-
ems, have made it possible to fine tune blood glucose
egulation to achieve excellent A1C levels with lower risk of
ypoglycemia.
With all forms of insulin therapy, the major risk is hypo-
lycemia; careful monitoring of both pre-prandial and post-
randial blood glucose concentrations and appropriate insulin
osage adjustments are required. As A1C approaches normal
alues, the risk of hypoglycemia increases and may become a
imiting factor to achieving the desired target. Factors such as
hanges in diet, physical exercise, emotional stress, or concur-
ent illness may require adjustments in insulin dosage. Addi-
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Insulin for Optimal Glycemic Control February 3, 2009:S21–7ionally, patients with altered gastric emptying caused by
astroparesis or with hypoglycemia unawareness may have
articular difficulty in adjusting insulin dosages to maintain
dequate glucose control.
Many recent technological advances, including the use
f insulin pens rather than traditional syringes and
eedles for insulin administration, have made it easier for
atients to use insulin therapy to manage their diabetes.
he newer models of insulin pens are convenient, easy to
se, and provide more accurate dosing than conventional
yringes and needles. The major disadvantage is that the
ens do not allow mixing of insulin for a single injection.
owever, this is not a practical problem because pre-
ixed insulins are available and current basal– bolus
egimens do not require mixing insulin preparations.
Finally, continuous glucose monitoring systems, which
ecord interstitial glucose concentrations for up to 7 days,
re excellent tools for determining fluctuations in glucose
hroughout the day, providing information needed to make
ppropriate adjustments in insulin therapy.
onclusions
yperglycemia, both in the fasting and the post-prandial
tates, is a major risk factor for microvascular and macro-
ascular damage in individuals with T2DM. Effective treat-
ent programs should be implemented early in the course
f the disease and adjusted at regular intervals to maintain
arget A1C levels as close to normal as possible, 7% at a
inimum, without causing an excessive risk of hypoglyce-
ia in individual patients.
Because of the progressive course of T2DM, primarily
ttributable to deterioration of pancreatic beta-cell function
nd ultimately loss of beta-cell mass, treatment with OADs
sually becomes less effective over time, necessitating insulin
eplacement therapy in many patients.
Initially, replacement of physiological basal insulin con-
entrations with a once-daily injection of a long-acting
odified insulin analog, in addition to continued use of
ADs, is sufficient to provide adequate glycemic control.
owever, many patients will eventually require multiple
aily injections of insulin, using a combination of long-
nd short-acting insulins in a basal– bolus approach to
ontrol both fasting and post-prandial glucose levels, or
he use of pre-mixed insulin preparations administered 2
o 3 times daily before meals. An alternative is the use of
n insulin pump to provide continuous subcutaneous
nsulin infusions.
A wide variety of insulin preparations are now available
hat make it easier to simulate the normal insulin secretory
attern. Improved insulin delivery systems, including insulin
ens and programmable insulin pumps, make it easier for
atients with T2DM to initiate and maintain insulin ther-
py to better regulate blood glucose control.eprint requests and correspondence: Dr. Edward S. Horton,
oslin Diabetes Center, One Joslin Place, Boston, Massachusetts
2215. E-mail: edward.horton@joslin.harvard.edu.
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